| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02787304 2016-000203-82 Details | 2019-11-25 Interventional | 2 | 197 | Volixibat Fatty Liver Non-alcoholic F… Non-Alcoholic S… | - At the Week 24 Interim Analysis, no differences were observed between any dose of Volixibat and placebo based on absolute change in steatosis from baseline, as assessed by MRI hepatic PDFF, and % change from baseline in ALT; the study was terminated. | |||
| NCT00765102 Details | 2019-11-25 Interventional | 2 | 32 | Bortezomib Romidepsin Multiple Myelom… Neoplasms, Plas… | There was a change in the Sponsor's research strategy; safety concerns were not a factor. - | |||
| NCT00655668 2007-002171-13 Details | 2019-11-25 Interventional | 2 | [1 Refs] | 54 | Lenalidomide Lymphoma Lymphoma, Non-H… Lymphoma, T-Cel… T-cell Non-Hodg… | Decision not to pursue as single agent in the study population. - | ||
| NCT00249002 Details | 2019-11-25 Interventional | 2 | 9 | Albumin-Bound P… Paclitaxel Hemodialysis Gr… | Terminated due to pipeline prioritization - | |||
| NCT04139915 Details | 2019-11-22 Interventional | 3 | 0 | Dactolisib Respiratory Tra… Clinically Symp… | Phase 3 trial RTB-101-204 study did not meet its primary endpoint - | |||
| NCT03529084 2017-003998-34 Details | 2019-11-22 Interventional | 3 | 0 | Erlotinib Hydro… Gefitinib Nazartinib Carcinoma, Non-… Carcinoma, Non-… | Decision by Sponsor not to continue with the trial. - | |||
| NCT03436732 Details | 2019-11-22 Interventional | 1 | 5 | LMB-100 Mesothelioma Mesothelioma, M… | Due to fatal occurrence (pneumonitis) attributed to one of the study drugs. - | |||
| NCT02908126 Details | 2019-11-22 Interventional | 1 | 4 | Oxytocin Hemorrhage Postpartum Hemo… Post Partum Hae… | No approval CA (MPA) of protocol amendment - | |||
| NCT02770014 Details | 2019-11-22 Interventional | 2 | 43 | Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Epidermal Growt… Non-Small Cell … | Terminated due to Osimertinib approval - | |||
| NCT01952054 Details | 2019-11-22 Interventional | 2 | 7 | Denosumab Breast Neoplasm… Breast Cancer | - - | |||
| NCT01127503 Details | 2019-11-22 Interventional | 2 | 2 | alpha-Methyltyr… DiGeorge Syndro… Mental Disorder… Psychotic Disor… Syndrome Psychosis Velo-cardio-fac… | Enrollment, study-design and execution challenges. - | |||
| NCT00456846 Details | 2019-11-22 Interventional | 2 | 123 | Albumin-Bound P… Paclitaxel Breast Neoplasm… Metastatic Brea… | - - | |||
| NCT00448539 2016-004950-14 Details | 2019-11-22 Interventional | 3 | 286 | Rufinamide Seizures Refractory Part… | The study was terminated early by the sponsor due to the discontinuation of clinical
development for rufinamide. This study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide. | |||
| NCT00415246 2006-001511-30 Details | 2019-11-22 Interventional | 3 | - | Triptorelin Pam… Prostatic Neopl… Prostate Cancer | The preliminary data do not support the expected sustainable blood levels of triptorelin for a
duration of 4 months in all patients. - | |||
| NCT00281528 Details | 2019-11-22 Interventional | 2 | [1 Refs] | 208 | Albumin-Bound P… Bevacizumab Paclitaxel Breast Neoplasm… Neoplasm Metast… Neoplasms | sufficient mature data to complete a final analysis - | ||
| NCT02954653 Details | 2019-11-21 Interventional | 1 | 8 | Azacitidine Cytarabine Daunorubicin Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | The study was terminated due to a change in sponsor prioritization. The study was terminated prematurely due to strategic business reasons and was not due to any safety concerns. | |||
| NCT02548962 Details | 2019-11-21 Interventional | 1/2 | 11 | Dexamethasone Ibrutinib Pomalidomide Multiple Myelom… Neoplasms, Plas… | After completing Phase 1, the Sponsor elected not to move forward with Phase 2. - | |||
| NCT01585415 Details | 2019-11-21 Interventional | 1 | 12 | Aldesleukin Cyclophosphamid… Fludarabine Vemurafenib Melanoma Metastatic Canc… | - - | |||
| NCT02679131 Details | 2019-11-20 Interventional | 1 | 18 | Belinostat Hematologic Neo… Neoplasms Renal Insuffici… Relapsed/Refrac… | Close out study w/o Cohort D; Severe Impairment (eGFR=15 to <30mL/min/1.73m²) - | |||
| NCT02746263 Details | 2019-11-19 Interventional | 4 | 1 | Acetaminophen Morphine Acute Pain Pain, Postopera… Acute Pain, Pos… | Business decision because enrollment was slower than expected Early termination leading to small number of participants analyzed. The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data. All AEs were listed, but not related to the study drug. |